Find Clinical Trial

Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day and Daflon 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD). International, multicenter, double-blind, randomized, parallel group study


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

Indicationvenous disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

MICRONISED PURIFIED FLAVONOID FRACTION,
S005682

Active Substance CodeS005682
Protocol CodeCL3-05682-105
EudraCT Code2012-003559-13


Documents and links

Lay summary
Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility